THCB Jun 21, 2014• By Cyndy Nayer and Leonard Kish When CMS approved Solvadi, Gilead’s $84,000 drug for hepatitis C, the stakes were raised in drug price wars. Two opposing forces, one, a financial push toward lower costs came up against an opposing force of public sentiment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Cyndy
Contact Cyndy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack